Table 1.
Oligoclonal and polyclonal antibody therapeutics in development
| Name | Disease | Antibodies | Developer | Clinical phase | Reference |
|---|---|---|---|---|---|
| Antibody cocktails: combining approved drug products | |||||
| Pertuzumab (anti-HER2) + Trastuzumab (anti-HER2) + chemotherapy | First-line treatment of HER2+ metastatic breast cancer | 2 | Genentech/Roche | Approved 2012 | NCT01120184, NCT00567190 [10, 11] |
| Epratuzumab (anti-CD22) + Rituximab (anti-CD20) + chemotherapy | Diffuse large B cell lymphoma | 2 | North Central Cancer Treatment Group | II complete | NCT00301821 [81] |
| Veltuzumab (anti-CD20) + Epratuzumab (anti-CD22) | B-cell acute lymphoblastic leukemia | 2 | Immunomedics | I/II | NCT01279707 |
| Veltuzumab (anti-CD20) + Milatuzumab (anti-CD74) | B-cell non-Hodgkin's lymphoma | 2 | Immunomedics | I/II (suspended) | NCT00989586 |
| 4E10 + 2F5 + 2G12 (gp120 + gp41) | HIV | 3 | Rockefeller University | I/II | NCT00219986 [32] |
| Antibody cocktails: new drug product | |||||
| MK3415A (CDA-1 + CDB-1) | Clostridium difficile infection | 2 | Merck/Medarex/MBL | Phase III | NCT01241552 [28] |
| Sym004 (non-overlapping epitopes on EGFR domain III) | Squamous cell cancer of the head and neck, solid tumors | 2 | Symphogen, Merck KGaA | Phase II | NCT01417936, NCT01117428 [13] |
| XTL-001 (HepeX-B) | Hepatitis B virus | 2 | Cubist | Phase IIb terminated | [30] |
| XOMA 3AB | Botulinum toxin A | 3 | Xoma/UCSF | Phase I | [20•] www.xoma.com |
| MM-151 | Non-overlapping epitopes on EGFR | 3 | Adimab | Phase I | www.adimab.com |
| – | H5N1 influenza | 2 | – | Preclinical | [82] |
| Anti-anthrax toxin (PA + LF) | Anthrax | 2 | – | Preclinical | [83] |
| Recombinant polyclonal antibodies | |||||
| Rozrolimupab (Sym001; anti-RhD) | Immune thrombocytopenic purpura (ITP) | 25 | Symphogen | II completed | NCT00718692 [40••] |
| CL184 | Rabies virus glycoprotein | 2 | Crucell Holland BV/Sanofi | II (fast-track) | NCT01228383 [26, 27•] |
| Sym013 EGFR, HER2, HER3 | Multiple cancer indications | 6 | Symphogen | Phase I | [84] |
| Sym002 | Smallpox (vaccinia) | 26 | Symphogen | Preclinical | [42••] |
| – | Methicillin-resistant S. aureus | 5 | Excelimmune | Preclinical | [44] |